BRAFTOVI is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

...after confirming that the tumour still harboured a BRAF p.V600E mutation, combined treatment with BRAF and MEK inhibitors was reintroduced….This time, the BRAF inhibitor encorafenib and MEK inhibitor binimetinib were given....At present, 3.5 years after initiation of treatment, the response is assessed as stable disease...we demonstrate that complete response and long-term PFS can be achieved in advanced LGSOC with combined BRAF and MEK inhibitor treatment.